FDA
-
-
-
-
-
-
-
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
-
-
-
-
-
-
-
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of AL001
-
-
-
-
-
-
-
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
-
-
-
-
-
-
-
BitNile (NILE) Reports Alzamend (ALZN) Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) to Report Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 in Mid-Late December
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

